LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SB590885 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 6154 | 5578 | 1.1031 | 1.1896 |
| SK-BR-3 | PIK-93 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4410 | 5578 | 0.7905 | 0.6150 |
| SK-BR-3 | KIN001-043 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 4206 | 5578 | 0.7539 | 0.5478 |
| SK-BR-3 | Alpelisib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3337 | 5578 | 0.5982 | 0.2615 |
| SK-BR-3 | Luminespib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2211 | 5578 | 0.3964 | -0.1094 |
| SK-BR-3 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1182 | 5578 | 0.2119 | -0.4485 |
| SK-BR-3 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2265 | 5578 | 0.4060 | -0.0917 |
| SK-BR-3 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 2543 | 4600 | 5578 | 0.8246 | 0.6777 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3312 | 5578 | 0.5937 | 0.2532 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4894 | 5578 | 0.8773 | 0.7745 |
| SK-BR-3 | WZ-4-145 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2737 | 5578 | 0.4907 | 0.0640 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2262 | 5578 | 0.4055 | -0.0926 |
| SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5182 | 5578 | 0.9290 | 0.8694 |
| SK-BR-3 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1281 | 5578 | 0.2297 | -0.4157 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2256 | 5578 | 0.4044 | -0.0947 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1788 | 5578 | 0.3206 | -0.2488 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1514 | 5578 | 0.2715 | -0.3391 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1140 | 5578 | 0.2044 | -0.4623 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1058 | 5578 | 0.1897 | -0.4894 |
| SK-BR-3 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 4405 | 5578 | 0.7897 | 0.6134 |
| SK-BR-3 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2493 | 5578 | 0.4469 | -0.0166 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5979 | 5578 | 1.0718 | 1.1319 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3902 | 5578 | 0.6995 | 0.4477 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4339 | 5578 | 0.7779 | 0.5918 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4214 | 5578 | 0.7554 | 0.5505 |